FY2028 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Equities research analysts at Zacks Research issued their FY2028 earnings estimates for Tonix Pharmaceuticals in a note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of $1.97 for the year. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share.

Several other analysts have also weighed in on TNXP. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Tonix Pharmaceuticals presently has a consensus rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock opened at $15.34 on Wednesday. The stock has a market cap of $205.56 million, a price-to-earnings ratio of -1.07 and a beta of 1.88. The stock has a 50 day moving average price of $15.58 and a 200-day moving average price of $18.17. Tonix Pharmaceuticals has a one year low of $13.07 and a one year high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of large investors have recently bought and sold shares of TNXP. Legal & General Group Plc bought a new position in Tonix Pharmaceuticals in the 2nd quarter valued at $25,000. State of Wyoming bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth $27,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals during the third quarter valued at $29,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $62,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Insider Activity at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 15,000 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following the completion of the purchase, the chief executive officer owned 15,001 shares in the company, valued at $223,364.89. This represents a 1,500,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.03% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.